Several small molecules and targeted agents, including immunomodulatory drugs (IMiDs) such as lenalidomide and pomalidomide, BTK-i like ibrutinib, zanubrutinib, and orelabrutinib, have been confirmed to exert antitumor effects in B-cell lymphomas by inhibiting BCR signaling and reducing NF-κB pathway activation. This evidence concerns the gene BCR and B-cell non-Hodgkin lymphoma.